NIH Starts Cutting Parts of Research Grant Funding
The main historical building of the National Institutes of Health (NIH) inside Bethesda campus Credit - Getty Images
The U.S. National Institutes of Health (NIH) is the largest funder of biomedical research in the world, and its grants create the foundation of basic science knowledge on which major health advances are built. On Feb. 7, the NIH announced that it would cut "indirect expenses" in the funding it provides to research grants by nearly half.
'We were all just dumbstruck,' says Dr. Richard Huganir, professor and chairman of the department of neuroscience at Johns Hopkins University School of Medicine, who relies on NIH grants for his research into therapies for autism and intellectual disabilities. 'I'm calling it the apocalypse of American science. This will basically change science as we know it in the U.S.'
"We're going to see health research kneecapped," says Dr. Otis Brawley, professor of oncology and epidemiology at the Johns Hopkins School of Medicine and the Bloomberg School of Public Health. Brawley has overseen grants at the National Cancer Institute (which is part of the NIH) as well as received them for his cancer research.
The funding cut took effect on Feb. 9 and targets indirect costs, which include facilities and administration costs.
In an immediate response, 22 states sued the NIH and the U.S. Department of Health and Human Services (which oversees NIH), calling the action 'unlawful' and saying it would 'devastate critical public health research at universities and research institutions in the United States.'
Hours later, the Massachusetts Attorney General issued a temporary restraining order preventing the NIH from immediately cutting billions in the grants it issues to scientists and their institutions.
Here's what to know about the ongoing funding turmoil at the NIH.
NIH awards around $30 to $35 billion in grants each year to a wide range of disease-related research projects. It helped fund the mRNA technology that eventually led to the recent COVID-19 vaccines, for example.
In a Feb. 7 post on X, the agency said about $9 billion of its annual research grant budget goes toward indirect costs, which are charged by academic institutions receiving the grants. Institutes that receive NIH grants negotiate indirect cost rates, taking into account how much they need to pay for things like heat, air conditioning, and electricity inside research facilities. Administrative costs include those required to comply with legal and regulatory requirements to conduct the research. Once a rate agreement is reached, it applies to all federal grants from NIH to that institution.
Read More: Why Are So Many Young People Getting Cancer? It's Complicated
Indirect costs can range from nearly 30% to 70% of a research grant, depending on the institution. Certain non-academic institutes that have fewer resources than academic universities tend to have higher indirect rates, from 90% to 100%, says Brawley. In its X post, the NIH says Harvard has charged 69%, Yale 67.5%, and Johns Hopkins 63.7% in indirect costs. (Johns Hopkins' rate recently changed to 55%, Brawley and Huganir say.) Under its new policy, the NIH would cap indirect costs for all institutions at 15%.
Huganir says indirect costs are essential for modern-day research. In addition to keeping the lights on in labs, they cover maintaining and staffing critical scientific equipment and resources such as animal facilities, DNA sequencing, and imaging.
'Right now we are in the middle of developing therapies that could really cure certain forms of intellectual disability for millions of kids across the world,' he says. 'We are terrified that the research is going to stop.'
The NIH did not immediately respond to a request about what prompted the change, directing journalists to the agency's Grants Policy Statement. However, Elon Musk—tasked by the Trump Administration to address efficiency in government spending—called out the high percentage of indirect costs that the NIH had been supporting. 'Can you believe that universities with tens of billions in endowments were siphoning off 60% of research award money for 'overhead?' he wrote on X on Feb. 7.
The 15% cap puts NIH grants in line with those from private philanthropic agencies that support research. The NIH says that these entities—such as the Gates Foundation, the Rockefeller Foundation, and the Chan Zuckerberg Initiative—allow a maximum of 10% to 15% of a research grant for indirect costs. But philanthropic foundations and academic institutes aren't comparable to the federal government when it comes to funding science, Brawley and Huganir say, since foundations tend to support more focused and specific endeavors, such as individual faculty members or targeted projects.
So far, it's unclear. In his post on X, Musk hinted that endowments should be part of the solution. But health experts say endowments aren't a consistent or practical source of funding for overhead costs, since many outline narrow purposes or projects for the funds that are legally allocated and can't be redirected to cover things like research expenses.
Read More: 8 Ways to Shorten Your Wait for a Doctor's Appointment
'Nobody else can really afford to pay for it,' says Brawley. 'What's worked nicely over the last 50 to 60 years is that the NIH does a lot of basic science research, asking questions that people can't make money from. And the corporations, including biotech, can swoop in, and take that basic science information and do engineering and turn it into things you can sell and treat diseases with.'
Without the funding to support indirect costs, much of the scientific work that has been a mainstay of the U.S. biomedical field may not happen, or would take much longer. 'The bottom line is that we are going to have a lot less resources, which obviously means we are going to have to lay people off, and research will be slowed down,' says Huganir.
Brawley is also concerned about the quashing effect such actions will have on young scientists to remain in the field and create new labs. 'Nobody wins the Nobel Prize for what they did when they were 50,' he says. 'I'm worried about the loss of creativity from young people; that's where all the really good ideas come from.'
Read More: 8 Symptoms Doctors Often Dismiss As Anxiety
He also notes that while a lot of attention has been focused on large academic universities with big endowments and deeper financial resources, the policy will likely have an even stronger impact on smaller community hospitals that supply many of the patients who participate in clinical trials. 'People who are getting treated in clinical trials now for cancer will find many of those trials will close down,' he says.
That will affect the pipeline of new treatments for diseases like cancer. Brawley says that drugs approved in the last six months have been tested in trials over the last decade, so curtailing funding in research today will slow down the pace of progress and eventually result in fewer drugs. 'I anticipate that the number of drugs approved is going to go down dramatically in the next five to 10 years,' he says.
'We have been working all weekend trying to calm faculty and students and everybody who is concerned about future careers in science,' says Huganir. 'We have lots of committees addressing different aspects of this, and we're trying to come up with ideas about how we can compensate for any losses we are experiencing."
"That may mean laying people off and maybe putting hiring freezes on new faculty," he says. "We will have to make up for the difference through cost cutting in some way.'
With the temporary restraining order, NIH grantees have some time to come up with a plan for how they will try to maintain the pace of scientific research with much less NIH support.
'Perhaps we need to reimagine or re-envision our entire system for how we fund science and how people make money off of science,' says Brawley. 'But the way to do that is not to threaten on Friday night to cut everybody's indirect [costs] down to 15%.'
Ultimately, scientists say the American public will pay a price for the drastic funding cuts. 'The American people should know that this is going to impact them—the health of their families and their children,' says Huganir. 'And the economies of communities around these institutions that get a lot of NIH funding are going to be impacted as well.'
Contact us at letters@time.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion
BioNTech will acquire all shares of CureVac after the two sides reached an agreement in a deal valued around $1.25 billion. Each share of CureVac, a clinical-stage biotech company, will be exchanged for about $5.46 in BioNTech American depositary shares. Upon the deal's closing, CureVac shareholders are expected to own between 4% and 6% of the German developer of RNA vaccines and immunotherapies. ICE Raids Have Sent Latino Shoppers Into Hiding and Big Brands Are Hurting The Secret to Retaining the Best Employees: Ask Them These Four Questions Here's How Much Money the U.S. Is Earning From Tariffs, in Charts How Home Depot Became Ground Zero in Trump's Deportation Push Supply Chains Become New Battleground in the Global Trade War BioNTech Chief Executive Ugur Sahin said the plan is to bring complementary capabilities between the two companies together to develop transformative cancer treatments. CureVac's operating subsidiary will become a wholly owned subsidiary of BioNTech following the close of the transaction. As part of this plan, BioNTech will integrate CureVac's research and manufacturing site in Tübingen, Germany. The deal was unanimously approved by both companies' management and supervisory boards. It is expected to close in 2025. Shares of CureVac surged 29% to $5.25 in premarket trading. Write to Denny Jacob at Pulls Outlook as Sales Fall Bojangles Is Exploring a Sale While the Fried-Chicken Market Is Hot Why Bosses Should Give Feedback in the Morning The Audacious Reboot of America's Nuclear Energy Program Muted May Inflation Defies Tariff Fears Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
Is Fidelity Select Portfolio Medical Technology and Devices (FSMEX) a Strong Mutual Fund Pick Right Now?
If you have been looking for Sector - Health funds, a place to start could be Fidelity Select Portfolio Medical Technology and Devices (FSMEX). FSMEX has a Zacks Mutual Fund Rank of 1 (Strong Buy), which is based on various forecasting factors like size, cost, and past performance. Zacks categorizes FSMEX as Sector - Health, a segment packed with options. Sector - Health mutual funds offer investors a focus on the healthcare industry, one of the largest sectors in the American economy. These funds can include everything from pharmaceutical companies to medical device manufacturers and for-profit hospitals. Fidelity is responsible for FSMEX, and the company is based out of Boston, MA. Fidelity Select Portfolio Medical Technology and Devices made its debut in April of 1998, and since then, FSMEX has accumulated about $4.48 billion in assets, per the most up-to-date date available. The fund is currently managed by Edward Yoon who has been in charge of the fund since May of 2007. Investors naturally seek funds with strong performance. This fund has delivered a 5-year annualized total return of 5.12%, and it sits in the middle third among its category peers. If you're interested in shorter time frames, do not dismiss looking at the fund's 3 -year annualized total return of 3.37%, which places it in the bottom third during this time-frame. It is important to note that the product's returns may not reflect all its expenses. Any fees not reflected would lower the returns. Total returns do not reflect the fund's [%] sale charge. If sales charges were included, total returns would have been lower. When looking at a fund's performance, it is also important to note the standard deviation of the returns. The lower the standard deviation, the less volatility the fund experiences. Over the past three years, FSMEX's standard deviation comes in at 18.22%, compared to the category average of 15.64%. Over the past 5 years, the standard deviation of the fund is 19.24% compared to the category average of 16.64%. This makes the fund more volatile than its peers over the past half-decade. Investors should note that the fund has a 5-year beta of 0.92, which means it is hypothetically less volatile than the market at large. Alpha is an additional metric to take into consideration, since it represents a portfolio's performance on a risk-adjusted basis relative to a benchmark, which in this case, is the S&P 500. With a negative alpha of -7.95, managers in this portfolio find it difficult to pick securities that generate better-than-benchmark returns. Costs are increasingly important for mutual fund investing, and particularly as competition heats up in this market. And all things being equal, a lower cost product will outperform its otherwise identical counterpart, so taking a closer look at these metrics is key for investors. In terms of fees, FSMEX is a no load fund. It has an expense ratio of 0.63% compared to the category average of 1.11%. Looking at the fund from a cost perspective, FSMEX is actually cheaper than its peers. While the minimum initial investment for the product is $0, investors should also note that there is no minimum for each subsequent investment. Fees charged by investment advisors have not been taken into considiration. Returns would be less if those were included. Overall, Fidelity Select Portfolio Medical Technology and Devices ( FSMEX ) has a high Zacks Mutual Fund rank, and in conjunction with its comparatively similar performance, average downside risk, and lower fees, Fidelity Select Portfolio Medical Technology and Devices ( FSMEX ) looks like a great potential choice for investors right now. Your research on the Sector - Health segment doesn't have to stop here. You can check out all the great mutual fund tools we have to offer by going to to see the additional features we offer as well for additional information. For analysis of the rest of your portfolio, make sure to visit for our full suite of tools which will help you investigate all of your stocks and funds in one place. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Get Your Free (FSMEX): Fund Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Newsweek
16 minutes ago
- Newsweek
Is Your Kitty Anxious? Be Aware of This Condition, Say Vets
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Cats are known to be skittish—but if yours is noticeably anxious, researchers are warning that you might want to be aware of one particular feline health condition. New research from the University of Montreal's Faculty of Veterinary Medicine has revealed a critical link between anxiety/stress and recurring bouts of a painful bladder condition—feline idiopathic cystitis (FIC). The team are urging cat owners and veterinarians to prioritize stress reduction for our more anxious furry companions. FIC is a leading cause of emergency vet visits and is characterized by acute bladder inflammation, painful and sometimes bloody urination in cats, according to the researchers. Traditionally, without detectable bacterial infections, stones or tumors, the condition is labeled as idiopathic—that is, with no "organic" cause. However, the team's study of 33 cats challenges this. A tabby cat hides and appears nervous. A tabby cat hides and appears nervous."A similar condition with the same symptoms occurs in women and is often linked to high levels of stress or anxiety," said veterinary behaviorist professor Marion Desmarchelier in a statement. "Some cats end up being euthanized because of it. The disease itself is not fatal, but the cost of repeated emergency treatments can be too much for some families." FIC has a high recurrence rate, with about half of affected cats having repeat episodes. A Connection With the COVID-19 Pandemic The University researchers also shed light on the connection between stress and cat health observed during the COVID-19 pandemic. When human companions stayed home, many cats—who are often known for their love of routine—found themselves disrupted. "We were home all the time during the pandemic," said paper co-author Marianne Caudron in a statement. "Dogs were thrilled because they got lots of walks, but we saw twice as many cases of idiopathic cystitis in cats." This observation prompted the team to launch their study, the results of which are published in the Journal of Veterinary Behavior. The research involved 33 cats diagnosed with FIC. Their owners completed a questionnaire about their cat's behavior—including their levels of aggression and fear—and details about their living environment. "We initially thought that anxious, aggressive cats would be more prone to recurrent cystitis, but it's actually the fearful, withdrawn ones that seem to be at greater risk," explained Desmarchelier. Treatment Should Focus on Mental Well-Being The study's authors advocate that the scope of FIC treatment should be expanded to include addressing cats' mental health. "We believe this condition is caused by stress and anxiety— and therefore should no longer be called idiopathic cystitis, but instead 'cystitis secondary to anxiety,'" Desmarchelier said. The study offered several practical ways to reduce feline stress, including increasing water sources in the home for cats, setting up an extra litter box than the number of cats in the home, offering a variety of toys and providing safe access to the outdoors. While these changes weren't shown to prevent all recurrences of cystitis, researchers believe they are crucial for risk reduction and overall well-being. Desmarchelier concluded with a hopeful message: "Taking a cat to the vet twice a year for a urinary blockage costs a fortune. But it doesn't have to be this way—there are solutions. That's the message we want to get across." Do you have a tip on a science story that Newsweek should be covering? Do you have a question about cats? Let us know via science@ Reference Caudron, M., Laroche, P., Bazin, I., & Desmarchelier, M. (2025). Association between behavioral factors and recurrence rate in cats with feline "idiopathic" cystitis. Journal of Veterinary Behavior, 78, 90–96.